ARTICLE | Clinical News
BrevaRex: Phase I
October 30, 2000 8:00 AM UTC
AXO said that preliminary results of a completed Phase I trial of BrevaRex in 17 patients with breast, colorectal and thyroid cancer showed that the antibody activated cellular immune responses (T cel...